111 related articles for article (PubMed ID: 8111707)
1. The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods.
Martensson G; Thylen A; Lindquist U; Hjerpe A
Cancer; 1994 Mar; 73(5):1406-10. PubMed ID: 8111707
[TBL] [Abstract][Full Text] [Related]
2. High-performance capillary electrophoretic analysis of hyaluronan in effusions from human malignant mesothelioma.
Karamanos NK; Hjerpe A
J Chromatogr B Biomed Sci Appl; 1997 Sep; 697(1-2):277-81. PubMed ID: 9342681
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.
Thylén A; Levin-Jacobsen AM; Hjerpe A; Martensson G
Eur Respir J; 1997 Feb; 10(2):404-8. PubMed ID: 9042640
[TBL] [Abstract][Full Text] [Related]
4. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.
Pettersson T; Fröseth B; Riska H; Klockars M
Chest; 1988 Nov; 94(5):1037-9. PubMed ID: 3180855
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.
Thylén A; Hjerpe A; Martensson G
Cancer; 2001 Sep; 92(5):1224-30. PubMed ID: 11571736
[TBL] [Abstract][Full Text] [Related]
6. High pleural fluid hyaluronan concentrations in rheumatoid arthritis.
Söderblom T; Pettersson T; Nyberg P; Teppo AM; Linko L; Riska H
Eur Respir J; 1999 Mar; 13(3):519-22. PubMed ID: 10232419
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
Mundt F; Nilsonne G; Arslan S; Csürös K; Hillerdal G; Yildirim H; Metintas M; Dobra K; Hjerpe A
PLoS One; 2013; 8(8):e72030. PubMed ID: 23991032
[TBL] [Abstract][Full Text] [Related]
8. Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.
Welker L; Müller M; Holz O; Vollmer E; Magnussen H; Jörres RA
Virchows Arch; 2007 Apr; 450(4):455-61. PubMed ID: 17377812
[TBL] [Abstract][Full Text] [Related]
9. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.
Atagi S; Ogawara M; Kawahara M; Sakatani M; Furuse K; Ueda E; Yamamoto S
Jpn J Clin Oncol; 1997 Oct; 27(5):293-7. PubMed ID: 9390204
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronan in pleural effusions and in serum.
Hillerdal G; Lindqvist U; Engström-Laurent A
Cancer; 1991 May; 67(9):2410-4. PubMed ID: 2013045
[TBL] [Abstract][Full Text] [Related]
11. Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases.
Mezger J; Calavrezos A; Drings P; Gatzemeier U; Kaukel E; Konietzko N; Koschel G; Lamerz R; von Pawel J; Römer W
Lung; 1994; 172(3):183-4. PubMed ID: 8201832
[No Abstract] [Full Text] [Related]
12. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
[TBL] [Abstract][Full Text] [Related]
14. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.
Segal A; Sterrett GF; Frost FA; Shilkin KB; Olsen NJ; Musk AW; Nowak AK; Robinson BW; Creaney J
Pathology; 2013 Jan; 45(1):44-8. PubMed ID: 23222247
[TBL] [Abstract][Full Text] [Related]
15. The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.
Lovrenski A; Panjković M; Tegeltija D; Latinović LT; Krcedinac J
Med Pregl; 2012; 65(1-2):5-8. PubMed ID: 22452231
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the value of fibronectin as a tumour marker in malignant pleural mesothelioma.
Emri S; Ustündağ Y; Budak T; Karakoca Y; Ozdemir O
Monaldi Arch Chest Dis; 1997 Aug; 52(4):335-8. PubMed ID: 9401361
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma.
Roboz J; Greaves J; Silides D; Chahinian AP; Holland JF
Cancer Res; 1985 Apr; 45(4):1850-4. PubMed ID: 3978644
[TBL] [Abstract][Full Text] [Related]
18. The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies.
Porcel JM; Esquerda A; Rodriguez-Panadero F; Martínez-Iribarren A; Bielsa S
J Thorac Oncol; 2011 Jan; 6(1):190-4. PubMed ID: 21079519
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.
Mårtensson G; Hagmar B; Zettergren L
Eur J Respir Dis; 1984 Apr; 65(3):169-78. PubMed ID: 6723826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
